Journal profile · RHEUMATOLOGY
Reumatismo
ISSN 0048-7449 · eISSN 2240-2683 · PAGEPress Publications · Italy
Reumatismo: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 1.2 (journal website); diamond open access (no APC); no APC; median 159 days to acceptance (31 articles, last 24 months); 297 articles in 2025; indexed in ESCI and Scopus.
Scope
Aims, scope and focus
Reumatismo is published by PAGEPress Publications and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Rheumatoid Arthritis Research and Therapies, Spondyloarthritis Studies and Treatments and Systemic Lupus Erythematosus Research, together about 36.8% of its articles. Its main subfields are Rheumatology. (generated from OpenAlex topic counts and CAS ranking data)
Manuscripts will be carefully scrutinized for evidence of plagiarism, duplication and data manipulation; in particular, images will be carefully examined for any indication of intentional improper modification. Any suspected misconduct ends up with a quick rejection and is then reported to the US Office of Research Integrity. Authors are requested to submit their papers electronically using the Reumatismo online submission and review website. The Publisher and Editor regret that they are not able to consider submissions that do not follow this procedure. Submission checklist You can use this list to carry out a final check of your submission before you send it to the journal for review. Please check the relevant section in this Guide for Authors for more details. Ensure that your work is written in correct English before submission. Ensure that the following items are present: One author (multiple corresponding authors are not allowed) has been designated as the corresponding author with contact details: E-mail address Full postal address All necessary files have been uploaded: Manuscript file Include keywords (no more than five) All figures (include relevant captions) All tables (including titles, description, footnotes) Ensure all figure and table citations in the text match the files provided Further considerations Please prepare your manuscript for the single-blind peer review; Ensure that all references mentioned in the Reference List are cited in the text, and vice versa Permission has been obtained for use of copyrighted material from other sources (including the Internet) A competing interests statement is provided, even if the authors have no competing interests to declare Journal policies detailed in this guide have been reviewed Referee suggestions and contact details provided, based on journal requirements Manuscript has been 'spell checked' and 'grammar checked'. Ensure that your work is written in correct English before submission. Note that submitted manuscripts will not go through language-focused copyediting with the journal prior to or after acceptance; language-focused copyediting is the responsibility of the authors prior to submission. Professional copyediting can help authors improve the presentation of their work and increase their chances of being taken on by a publisher. In case you feel that your manuscript would benefit from a professional English language copyediting checking language grammar and style, you can find a reliable r
From the journal's Aims & Scope
Research area (LetPub): RHEUMATOLOGY
Editor-in-chief M.A. CimminoPublisher website
Editorial board by country: none in mainland China; most named Italy 45, United Kingdom 2 (47 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Rheumatoid Arthritis Research and TherapiesMedicine16.2%
- Spondyloarthritis Studies and TreatmentsMedicine10.8%
- Systemic Lupus Erythematosus ResearchMedicine9.8%
- Systemic Sclerosis and Related DiseasesMedicine9.1%
- Vasculitis and related conditionsMedicine5%
- Inflammatory Myopathies and DermatomyositisMedicine4.9%
- Autoimmune and Inflammatory Disorders ResearchMedicine4.7%
- Psoriasis: Treatment and PathogenesisImmunology and Microbiology4.1%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Rheumatology | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Rheumatology | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
Database indexing
ESCIScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
Web of SciencePubMedPublisher website
Other: Google Scholar, Scilit, OpenAlex
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor (publisher)
- 1.2Publisher website ·
- CiteScore 2026-06
- 1.5LetPub ·
- CiteScore (publisher)
- 1.5Publisher website ·
- SJR 2026-06
- 0.28LetPub ·
- SNIP 2026-06
- 0.41LetPub ·
- h-index
- 39OpenAlex ·
- i10-index
- 325OpenAlex ·
- 2-year mean citedness
- 0.41OpenAlex ·
- Self-citation rate
- 8.3%LetPub ·
- Share of gold OA articles
- 86.11%LetPub ·
Volume
- Articles per year
- 38LetPub ·
Articles by year OpenAlex count · 1,450 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 56 | 56 | 2 |
| 2025 | 297 | 297 | 27 |
| 2024 | 50 | 50 | 136 |
| 2023 | 44 | 44 | 133 |
| 2022 | 28 | 28 | 131 |
| 2021 | 32 | 32 | 333 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
159 daysMedian, submission to acceptance · P25–P75 119 days – 221 days
- Acceptance to online
- median 57 days (31 articles)
- Submission to online
- median 236 days
- Sample
- 31 articles with submission and acceptance dates (60 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 10 weeksLetPub ·
- Submission to publication (journal-reported)
- about 10 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Diamond open access (no APC)DOAJ
Every article is open access and authors pay no article processing charge.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | No APC | No | CC BY-NC | |
| LetPub | No APC | No | — | |
| Publisher website | Yes, amount not published | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare3 items from the author guidelines
- Keywords
- ≤ 5
- Reference style
- Numbered, in order of citation
- Suggested reviewers
- Required
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, Peer review, Self-archiving
- AI use Generative artificial intelligence (AI) and AI-assisted technologies
This policy establishes transparency standards for authors, readers, reviewers, and editors regarding the use of Generative AI and AI-assisted technologies in the writing process. It does not govern the use of AI tools for data analysis or the generation of research insights. PAGEPress will monitor developments in this field and revise this policy as needed in response to the rapid evolution of AI…
Source ↗Publisher website ·- Authorship Authorship and Contributorship
All persons designated as authors should qualify for authorship according to the ICMJE criteria. Each author should have participated sufficiently in the work to take public responsibility for the content. Authorship credit should only be based on substantial contributions to each of the following: i) conception and design, or analysis and interpretation of data, to ii) drafting the article or rev…
Source ↗Publisher website ·- Conflicts of interest Disclosures
Please read this advice and download the associated files. The International Committee of Medical Journal Editors has recently published in all ICMJE journals an editorial introducing a new “Disclosure Form for Potential Conflict of Interest”, with the aim to establish uniform reporting system, which can go over the existing differences in current formats or editors’ requests. We at PAGEPress Publ…
Source ↗Publisher website ·- Peer review Peer-review process
All submissions to Reumatismo are first checked for completeness (criteria for desk reject are available in the Guide for Authors) before being sent to an Editor, who decides whether they are suitable for peer review. If an Editor is on the author list or has a competing interest in a particular manuscript, another member of the Editorial Board will be assigned to oversee peer review. When making …
Source ↗Publisher website ·- Self-archiving
Official Journal of the Italian Society of Rheumatology. Founded in 1949. Model summary
Official Journal of the Italian Society of Rheumatology. Founded in 1949.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- PAGEPress Publications
- Country or region
- Italy
- Language
- English, Italian
- ISSN
- 0048-7449
- Electronic ISSN
- 2240-2683
- Society / sponsor
- Italian Society of Rheumatology
- Latest issue on the website
- Volume 78, Issue 2 (2026)
- Official links
- Journal homepage ↗LetPub
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Reumatismo
What CAS zone is Reumatismo in?
In the 2025 upgraded edition of the CAS Journal Ranking, Reumatismo is in Zone 4 of Medicine, and in Zone 4 of the minor category Rheumatology. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Reumatismo?
The journal's website gives an impact factor of 1.2; this is the journal's own figure, as LetPub lists none for it; CiteScore 1.5, h-index 39.
How long does peer review take at Reumatismo?
Based on the dates recorded on 31 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 159 days (interquartile range 119–221 days); authors report an average review time of about 10 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Reumatismo?
According to the journal's author guidelines: Keywords: ≤ 5; Reference style: Numbered, in order of citation; Suggested reviewers: Required. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Reumatismo based?
Of the 47 board members whose country the journal's board page names, none are in mainland China; the countries named most often are Italy (45) and United Kingdom (2). Counted from the institutions listed on the board page; for reference only.
Which databases index Reumatismo?
According to LetPub and DOAJ records, Reumatismo is indexed in ESCI, Scopus and DOAJ. The journal's website also lists Web of Science and PubMed; that list has not been checked against each database.
Is Reumatismo open access, and what is the APC?
Reumatismo is a diamond open-access journal (no APC). It charges no article processing charge.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-28). Last updated: .